Objective and Subjective Evaluation of Ophthalmic Lenses With Extra Power
Primary Purpose
Asthenopia
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Ophthalmic lens with extra power
Sponsored by
About this trial
This is an interventional other trial for Asthenopia
Eligibility Criteria
Inclusion Criteria:
- Subjective report of visual fatigue
- Non-presbyopes
- Permanent wearers who wear glasses for at least 5 hours a day
- Distance refractive error within the range of [+6.00 to -6.00]* (with cylinder in the negative form),
- Cylindrical component of the refractive error within the range of 0 to 2 D in both eyes,
- Anisometropia ≤ 1.00 D in sperical equivalent,
- Visual acuity of +0.10 logMAR or better in each eye with new prescription at distance (high contrast/high luminance),
- Distance visual acuity difference ≤0.20 logMAR between right and left eye (high contrast, high luminance)
- Near binocular visual acuity of +0.10 logMAR or better with a new prescription (high contrast, high luminance),
- Study frame characteristics: Frame B size at least 22 mm
Exclusion Criteria:
- Vulnerability of the subject,
- Participation in another study which might have an influence on vision or interfere with study assessments,
- Binocular vision problems,
- Known ocular pathology (e.g., age-related macular degeneration, glaucoma…),
- Any previous ocular surgery which might have an influence on vision or interfere with study assessments (e.g., iridectomy, refractive surgery…),
- Any untreated and/or uncontrolled systemic condition which might have an influence on vision, or interfere with study assessments (e.g., uncontrolled diabetes, uncontrolled high blood pressure…),
- Any medical treatment or medication that might have an influence on vision or interfere with study assessments (e.g., antidepressants, drugs with atropinic effects…),
- Knowledge/expertise in optometry, ophthalmic lenses, or optics based on past or current professional activity (e.g., optometrists, opticians, ophthalmologists…)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Other
Other
Arm Label
20-29 years (+0.40D extra power)
30-35 years (+0.40D extra power)
20-29 years (+0.40D extra power with blue cut)
Arm Description
Outcomes
Primary Outcome Measures
The difference in number of participants with treatment-related adverse events between the two lenses
Any untoward medical occurrence, unintended disease or injury, or any untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons whether or not related to the investigational medical device. Determined by subject's spontaneous reporting, the Investigator's non-leading questioning and his/her evaluation.
Secondary Outcome Measures
Full Information
NCT ID
NCT05089240
First Posted
September 28, 2021
Last Updated
October 10, 2021
Sponsor
Essilor International
Collaborators
Elite School of Optometry and Sankara Nethralaya
1. Study Identification
Unique Protocol Identification Number
NCT05089240
Brief Title
Objective and Subjective Evaluation of Ophthalmic Lenses With Extra Power
Official Title
Data Collection of Objective Parameters and Subjective Feedback on Visually Fatigued Subjects and Evaluation of the Effect of Ophthalmic Lenses to Alleviate Visual Fatigue
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
June 6, 2016 (Actual)
Primary Completion Date
December 2, 2016 (Actual)
Study Completion Date
July 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Essilor International
Collaborators
Elite School of Optometry and Sankara Nethralaya
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To evaluate subjective visual performance and objective visual parameters when wearing ophthalmic lenses with extra power (+0.4 D or +0.6 D), and ophthalmic lenses with a selective blue cut filter.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthenopia
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
127 (Actual)
8. Arms, Groups, and Interventions
Arm Title
20-29 years (+0.40D extra power)
Arm Type
Other
Arm Title
30-35 years (+0.40D extra power)
Arm Type
Other
Arm Title
20-29 years (+0.40D extra power with blue cut)
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Ophthalmic lens with extra power
Primary Outcome Measure Information:
Title
The difference in number of participants with treatment-related adverse events between the two lenses
Description
Any untoward medical occurrence, unintended disease or injury, or any untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons whether or not related to the investigational medical device. Determined by subject's spontaneous reporting, the Investigator's non-leading questioning and his/her evaluation.
Time Frame
Immediately after the first and second wearing period (21 days each)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Subjective report of visual fatigue
Non-presbyopes
Permanent wearers who wear glasses for at least 5 hours a day
Distance refractive error within the range of [+6.00 to -6.00]* (with cylinder in the negative form),
Cylindrical component of the refractive error within the range of 0 to 2 D in both eyes,
Anisometropia ≤ 1.00 D in sperical equivalent,
Visual acuity of +0.10 logMAR or better in each eye with new prescription at distance (high contrast/high luminance),
Distance visual acuity difference ≤0.20 logMAR between right and left eye (high contrast, high luminance)
Near binocular visual acuity of +0.10 logMAR or better with a new prescription (high contrast, high luminance),
Study frame characteristics: Frame B size at least 22 mm
Exclusion Criteria:
Vulnerability of the subject,
Participation in another study which might have an influence on vision or interfere with study assessments,
Binocular vision problems,
Known ocular pathology (e.g., age-related macular degeneration, glaucoma…),
Any previous ocular surgery which might have an influence on vision or interfere with study assessments (e.g., iridectomy, refractive surgery…),
Any untreated and/or uncontrolled systemic condition which might have an influence on vision, or interfere with study assessments (e.g., uncontrolled diabetes, uncontrolled high blood pressure…),
Any medical treatment or medication that might have an influence on vision or interfere with study assessments (e.g., antidepressants, drugs with atropinic effects…),
Knowledge/expertise in optometry, ophthalmic lenses, or optics based on past or current professional activity (e.g., optometrists, opticians, ophthalmologists…)
12. IPD Sharing Statement
Learn more about this trial
Objective and Subjective Evaluation of Ophthalmic Lenses With Extra Power
We'll reach out to this number within 24 hrs